[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cerebral-amyloid-angiopathy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cerebral-amyloid-angiopathy":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,42,70,99,119,141,169,196],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100612165","phase-3-jiedu-huayu-oral-prescription-in-the-treatment-of-intracranial-hemorrhage-associated-with-cerebral-amyloid-angiopathy-100612165",false,"NCT07250035","Jiedu Huayu Oral Prescription in the Treatment of Intracranial Hemorrhage Associated With Cerebral Amyloid Angiopathy","A Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Study of Jiedu Huayu Oral Prescription in the Treatment of Intracranial Hemorrhage Associated With Cerebral Amyloid Angiopathy","CHN-CAA","Inclusion Criteria:\n\n* ① Possible or very likely CAA-ICH;\n\n  * Within 7 days of onset; ③ Primary supratentorial intracerebral hemorrhage (bleeding volume ≤40ml);\n\n    * GCS≥8 points;\n\n      * NIHSS score ≤25 points; ⑥50≤age≤90 years old; ⑦ Gender is not limited; ⑧ The subject or their legal representative gives informed consent and signs the informed consent form.\n\nExclusion Criteria:\n\n* Those who are known to be allergic to the components of the traditional Chinese medicine compound used in the experiment;\n\n  * It is known that after treatment with vascular malformations, aneurysms, coagulation disorders, anticoagulant or antiplatelet drugs, Intracranial conditions caused by clear etiologies such as thrombolytic therapy, post-infarction hemorrhage transformation, hematological diseases, moyamoya disease, etc;\n\n    * Patients with traumatic intracranial hemorrhage;\n\n      * Patients with active peptic ulcers or other clear tendencies of rebleeding;\n\n        * Patients with severe liver or kidney dysfunction (Note: Severe liver dysfunction is defined as ALT or AST being greater than.\n\n          ⑥ Those who have received or are planning to undergo surgical treatment;\n\n          ⑦ Those who suffer from other life-threatening serious diseases and have an expected survival time of less than six months;\n\n          ⑧ Other conditions that significantly limit the evaluation of neurological function, prevent the completion of cranial magnetic resonance imaging, or affect the follow-up of patient;\n\n          ⑨ Pregnant women, those planning to become pregnant or lactating women;\n\n          ⑩Those who are currently participating in other interventional clinical trials.","ALL","50 Years","90 Years",{"count":21,"type":22},436,"ESTIMATED","INTERVENTIONAL",[25],"PHASE3","Cerebral hemorrhage, as a serious cerebrovascular disease, has the highest disability rate and mortality rate among all types of cerebrovascular diseases .It has brought a heavy burden to society. In China, the incidence of cerebral hemorrhage is much higher than that in Europe and America, and cerebral amyloid angiopathy (CAA) is one of the causes of primary cerebral hemorrhage However, there are relatively few related studies. Therefore, the research object of this subject focuses on patients with cerebral amyloid angiopathy, in view of their high recurrence rate of vascular events and the lack of treatment methods.It aims to deeply explore the detoxification and blood stasis removal treatment plan combining traditional Chinese and Western medicine to reduce vascular events for patients.",[28],"Cerebral Amyloid Angiopathy","RECRUITING","2026-06-23",{"date":32,"type":33},"2026-06-24","ACTUAL",{"date":35,"type":33},"2026-01-30",{"date":37,"type":22},"2028-11-30",{"name":39,"class":40},"Beijing Tiantan Hospital","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":17,"minAge":50,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":23,"phases":53,"briefSummary":55,"conditions":56,"keywords":57,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":69},"100546344","phase-2-a-phase-2-trial-of-aln-app-in-patients-with-cerebral-amyloid-angiopathy-100546344","NCT06393712","A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy","A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Intrathecally Administered ALN-APP in Patients With Cerebral Amyloid Angiopathy (CAA)","cAPPricorn-1","Inclusion Criteria (sporadic CAA patients):\n\n* Is 50 years or older\n* Has probable CAA per the Boston Criteria Version 2.0\n\nInclusion Criteria (Dutch-type CAA patients):\n\n* Is 30 years or older\n* Has known E693Q amyloid precursor protein (APP) gene mutation for Dutch-type CAA\n\nExclusion Criteria:\n\n* Moderate or severe stage Alzheimer's disease (AD) or significant cognitive impairment (CI)\n* Has a history of previous clinical intracerebral hemorrhage (ICH) with onset less than 90 days prior to anticipated randomization in the study\n* Has alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \\>3×upper limit of normal (ULN) at Screening\n* Has estimated glomerular filtration rate (eGFR) \\\u003C30 mL\u002Fmin\u002F1.73m\\^2 at Screening\n* Has recently received an investigational agent\n* Has had treatment with amyloid-targeting antibody\n\nNote: other protocol defined inclusion \u002F exclusion criteria apply","30 Years",{"count":52,"type":22},200,[54],"PHASE2","The purpose of the study is to evaluate the effect of ALN-APP on measures of CAA disease progression and to characterize the safety, tolerability, and pharmacodynamics (PD) of ALN-APP in adult patients with sporadic CAA (sCAA) and Dutch-type CAA (D-CAA). The study will be conducted over 2 periods: a 24-month double-blind treatment period and an optional 18-month open-label extension (OLE) period. The estimated duration of study participation, inclusive of screening, treatment, and additional safety follow-up, is up to 50 months.",[28],[58],"CAA","2026-06-10",{"date":61,"type":33},"2026-06-12",{"date":63,"type":33},"2024-05-17",{"date":65,"type":22},"2029-12-14",{"name":67,"class":68},"Alnylam Pharmaceuticals","INDUSTRY",57,{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":74,"acronym":75,"eligibilityCriteria":76,"healthyVolunteers":11,"sex":17,"minAge":77,"maxAge":4,"enrollmentInfo":78,"targetDuration":4,"studyType":23,"phases":80,"briefSummary":82,"conditions":83,"keywords":86,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":41},"100570965","application-of-digital-twins-technology-in-patients-who-had-a-stroke-with-moyamoya-disease-and-with-cerebral-amyloid-angiopathy-caa-during-the-secondary-prevention-phase-a-proof-of-concept-using-a-randomized-control-trial-clinical-study-6-stratif-ai-project-100570965","NCT06714097","Application of Digital Twins' Technology in Patients Who Had a Stroke, With Moyamoya Disease and With Cerebral Amyloid Angiopathy (CAA) During the Secondary Prevention Phase: A Proof of Concept Using a Randomized Control Trial (Clinical Study 6, STRATIF-AI Project)","SMART","Inclusion Criteria:\n\n* People aged ≥ 18\n* Clinical and neuroradiological diagnosis of stroke (TAC or MR); diagnosis of CAA based on Boston 2.0 criteria; diagnosis of Moyamoya disease based on diagnostic criteria 2021.\n* MOCA total score ≥ 23\n* modified Rankin Scale (mRS) ≤ 2\n* First-time patients at the Besta Institute\n* Ability to sign informed consent\n* Possibility of performing a brain MRI\n\nExclusion Criteria:\n\n* Patients with transient neurological deficits that resolve within an hour and normal brain imaging\n* Patient under legal protection or deprived of liberty by judicial or administrative decision\n* Patient whose follow-up will be impossible\n* Contraindication to magnetic resonance imaging and\u002For Digital subtraction angiography (DSA)\n* Pregnant patients\n* Known or suspected drug or alcohol abuse","18 Years",{"count":79,"type":22},20,[81],"NA","The goal of this clinical trial is to obtain initial feedback on the implementation of the STRATIF-AI platform and digital twin in the secondary prevention phase in patients with stroke, Moyamoya disease and Cerebral amyloid angiopathy, including adults of both sexes.\n\nThe main questions it aims to answer is: how is the patients' experience regarding the use of the STRATIF-AI platform? Researchers will compare Arm 1, who use the STRATIF-AI app in addition to standard secondary prevention, against Arm 2, who receive standard secondary prevention only, to collect feedback regarding the platform usability.\n\nParticipants in the Arm 1 will:\n\n* Complete cognitive and psychological assessments at the time of the first visit and after six months\n* Follow the indications received from the clinician for standard secondary prevention\n* Use the STRATIF-AI app daily for health management\n* Optionally, purchase wearable devices that connect to the app.\n* Participate in interviews at the six-month mark to share their experiences with the app.\n\nPatients in the Arm 2 will:\n\n* Complete cognitive and psychological assessments at the time of the first visit and after six months\n* Follow the indications received from the clinician for standard secondary prevention",[84,85,28],"Stroke","Moyamoya Disease",[87,88,89,85,28],"stroke","secondary prevention","digital twin","2026-03-25",{"date":92,"type":33},"2026-03-30",{"date":94,"type":22},"2026-04",{"date":96,"type":22},"2027-04",{"name":98,"class":40},"Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta",{"id":100,"slug":101,"hasResults":11,"nctId":102,"briefTitle":103,"officialTitle":104,"acronym":105,"eligibilityCriteria":106,"healthyVolunteers":11,"sex":17,"minAge":107,"maxAge":4,"enrollmentInfo":108,"targetDuration":4,"studyType":110,"phases":4,"briefSummary":111,"conditions":112,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":113,"startDateStruct":114,"completionDateStruct":116,"leadSponsor":118,"locationsCount":41},"100378214","searching-biomarkers-cerebral-amyloid-angiopathy-seneca-100378214","NCT04204642","SEarchiNg biomarkErs Cerebral Amyloid Angiopathy (SENECA)","SEarchiNg biomarkErs Cerebral Amyloid Angiopathy (SENECA): Italian Network for the Study of CAA","SENECA","Inclusion Criteria:\n\n* All consecutive patients ≥55 years (with the exception of genetic cases), referred to the participating centres, with a diagnosis of possible probable and definite symptomatic or asymptomatic CAA, defined according to the modified Boston neuroradiological criteria, who had undergone at least one brain MRI (mandatory requirement for inclusion of the patient in the study) will be recruited.\n\nExclusion Criteria:\n\n* evidence of other causes of cerebral hemorrhage (brain tumors, arteriovenous malformations, aneurysms, cavernous angiomas), contraindications to brain MRI, pregnancy and breastfeeding","55 Years",{"count":109,"type":22},500,"OBSERVATIONAL","Cerebral amyloid angiopathy (CAA) is one of the major types of cerebral small vessel disease, and a leading cause of spontaneous intracerebral hemorrhage and cognitive decline in elderly patients. Although increasingly detected, a number of aspects including the pathophysiology, the clinical and neuroradiological phenotype and the disease course are still under investigation. The incomplete knowledge of the disease limits the implementation of evidence based guidelines on patient's clinical management and the development of treatments able to prevent or reduce disease progression.\n\nThe SENECA (SEarchiNg biomarkErs of Cerebral Angiopathy) project is the first Italian multicentre cohort study aimed at better defining the disease natural history and identifying clinical and neuroradiological markers of disease progression. By a multidisciplinary approach and the collection of a large and well phenotyped series and biorepository of CAA patients, the study is ultimately expected to improve the diagnosis and the knowledge of CAA pathophysiological mechanisms.",[28],{"date":92,"type":33},{"date":115,"type":33},"2020-06-01",{"date":117,"type":22},"2027-11-01",{"name":98,"class":40},{"id":120,"slug":121,"hasResults":11,"nctId":122,"briefTitle":123,"officialTitle":124,"acronym":4,"eligibilityCriteria":125,"healthyVolunteers":11,"sex":17,"minAge":77,"maxAge":4,"enrollmentInfo":126,"targetDuration":4,"studyType":23,"phases":128,"briefSummary":129,"conditions":130,"keywords":131,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":132,"lastUpdatePostDateStruct":133,"startDateStruct":135,"completionDateStruct":137,"leadSponsor":139,"locationsCount":41},"100493758","phase-2-a-study-of-amdx-2011p-in-participants-with-caa-100493758","NCT05709314","A Study of AMDX-2011P in Participants With CAA","A Phase 2, Open-Label Study of AMDX-2011P as a Retinal Tracer in Participants With Cerebral Amyloid Angiopathy (CAA)","Inclusion Criteria:\n\n1. Diagnosis of hereditary CAA or probable and definite symptomatic or asymptomatic sporadic CAA diagnosed through genetic testing or according to the modified Boston neuroradiological criteria, who had undergone at least one brain magnetic resonance imaging (MRI)prior to entry into study.\n2. Abnormality consistent with CAA on historical MRI.\n3. In general good health\n\nExclusion Criteria:\n\n1. Presence of any underlying physical or psychological medical condition that, in the opinion of the investigator, would make it unlikely that the participant will complete the study per protocol.\n2. Clinically significant laboratory abnormalities assessed by the investigator.\n3. Active malignancy and\u002For history of malignancy in the past 5 years, with the exception of completely excised non-melanoma skin cancer or low-grade cervical intraepithelial neoplasia.\n4. Prolonged QTcF (\\>450 ms for males and \\>470 ms for females),cardiac arrhythmia, or any clinically significant abnormality in the resting ECG, as judged by the investigator.",{"count":127,"type":22},25,[54],"The purpose of this study is to assess safety, tolerability, plasma pharmacokinetics and biologic activity of a single intravenous dose of AMDX-2011P in participants with cerebral amyloid angiopathy (CAA).",[28],[58],"2026-02-11",{"date":134,"type":33},"2026-02-13",{"date":136,"type":33},"2024-07-09",{"date":138,"type":22},"2026-12",{"name":140,"class":68},"Amydis Inc.",{"id":142,"slug":143,"hasResults":11,"nctId":144,"briefTitle":145,"officialTitle":146,"acronym":147,"eligibilityCriteria":148,"healthyVolunteers":11,"sex":17,"minAge":107,"maxAge":4,"enrollmentInfo":149,"targetDuration":4,"studyType":23,"phases":151,"briefSummary":152,"conditions":153,"keywords":155,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":159,"lastUpdatePostDateStruct":160,"startDateStruct":162,"completionDateStruct":164,"leadSponsor":166,"locationsCount":168},"100595018","phase-2-colchicine-for-the-prevention-of-recurrence-in-cerebral-amyloid-angiopathy-related-intracerebral-hemorrhage-100595018","NCT07026994","Colchicine for the Prevention of Recurrence in Cerebral Amyloid Angiopathy RElated IntraCerebral Hemorrhage","Colchicine for the Prevention of Recurrence in Cerebral Amyloid Angiopathy RElated IntraCerebral Hemorrhage (CARE-ICH)","CARE-ICH","Inclusion Criteria:\n\n* Age ≥55 years;\n* Diagnosed with \"probable CAA with supporting pathology\" or \"probable CAA\" according to the modified Boston criteria (version 1.5);\n* High risk of recurrent ICH, defined as: 1 prior symptomatic ICH and presence of cortical superficial siderosis (cSS), or ≥2 prior symptomatic ICHs;\n* Time interval since symptom onset of the most recent ICH: ≤3 months (earlier enrollment is preferred if criteria are met);\n* Modified Rankin Scale (mRS) score ≤4 at randomization;\n* Written informed consent from the participant or their legally authorized representative before study enrollment.\n\nExclusion Criteria:\n\n* Secondary causes of ICH;\n* Pre-existing moderate-to-severe renal, liver or blood disorders (anaemia \\[hemoglobin \\\u003C10g\u002FdL\\], thrombocytopaenia \\[platelet count \\\u003C100×109\u002FL\\], leucopenia \\[white blood cell \\\u003C3×109\u002FL\\], cirrhosis or severe hepatic dysfunction, renal insufficiency \\[estimated glomerular filtration rate (eGFR) \\\u003C15mL\u002Fmin\\]);\n* Prior diagnosis of gout, peripheral neuropathy, myopathy, inflammatory bowel disease or chronic diarrhea;\n* Concurrent treatment with regular immune-suppressant (corticosteroids, cyclophosphamide, azathioprine, mycophenolate mofetil, rituximab), moderate-to-strong CYP3A4 inhibitors (atazanavir, clarithromycin, darunavir\u002Fritonavir, indinavir, itraconazole, ketoconazole, lopinavir\u002Fritonavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, tipranavir\u002Fritonavir) or P-glycoprotein inhibitors (cyclosporine, ranolazine);\n* Known allergy, sensitivity or intolerance to colchicine;\n* Contraindications or inability to complete brain MRI or susceptibility weighted imaging (SWI) scans;\n* Pregnancy or breastfeeding;\n* Recent participation in any other interventional study in the past 30 days before enrollment;\n* Not expected to survive the follow-up period;\n* Inability to adhere to study procedures;\n* Any condition in which investigators believe that participating in this study may be harmful to the patient.",{"count":150,"type":22},80,[54],"The goal of this clinical trial is to assess the safety and tolerability of colchicine for preventing intracerebral haemorrhage (ICH) recurrence in patients with cerebral amyloid angiopathy (CAA)-ICH at high risk of recurrence.\n\nThe main questions it aims to answer are:\n\n* Is colchicine safe for CAA-ICH patients?\n* Is colchicine well tolerated for CAA-ICH patients? Researchers will compare colchicine to a placebo (a look-alike substance that contains no drug) to see if colchicine is safe and tolerable for CAA-ICH patients and works to prevent ICH recurrence.\n\nParticipants will:\n\n* Take colchicine or a placebo every day for 12 months\n* Receive telephone follow-ups at 3 and 9 months, and visit the clinic at 6 and 12 months for checkups and tests\n* Control blood pressure and improve lifestyle",[28,154],"Intracerebral Hemorrhage Lobar",[28,156,157,158],"Intracerebral Hemorrhage","Colchicine","Recurrence","2025-06-22",{"date":161,"type":33},"2025-06-26",{"date":163,"type":33},"2025-06-18",{"date":165,"type":22},"2027-12",{"name":167,"class":40},"Huashan Hospital",3,{"id":170,"slug":171,"hasResults":11,"nctId":172,"briefTitle":173,"officialTitle":174,"acronym":175,"eligibilityCriteria":176,"healthyVolunteers":11,"sex":17,"minAge":77,"maxAge":4,"enrollmentInfo":177,"targetDuration":4,"studyType":110,"phases":4,"briefSummary":179,"conditions":180,"keywords":182,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":188,"lastUpdatePostDateStruct":189,"startDateStruct":191,"completionDateStruct":193,"leadSponsor":195,"locationsCount":41},"100587809","effect-of-the-mediterranean-diet-in-patients-affected-by-cadasil-and-cerebral-amyloid-angiopathy-100587809","NCT06933212","Effect of the Mediterranean Diet in Patients Affected by CADASIL and Cerebral Amyloid Angiopathy.","Effetto Della DIETa mEdiTerranea Sull'Incidenza di Ictus e Sul Decadimento Cognitivo in Pazienti Affetti da Cadasil e Angiopatia Cerebrale Amiloide","DIETETICA","Inclusion Criteria:\n\n* The study will include individuals of both sexes aged 18 years or older with a diagnosis of CADASIL (confirmed genetically by the presence of the NOTCH3 gene mutation) or possible\u002Fprobable CAA (defined according to the Boston 2.0 criteria). All participants must provide informed consent for the use of demographic, clinical, and nutritional data for scientific purposes in an anonymous form\n\nExclusion Criteria:\n\n* na",{"count":178,"type":22},86,"The study is divided into two phases: Phase 1 (observational) and Phase 2 (dietary intervention). The goal of Phase 1 is to assess the nutritional status and dietary habits of two cohorts of patients with CADASIL and CAA. A specific aim is to evaluate adherence to the Mediterranean Diet. The objectives include analyzing patients' nutritional status, lean and fat mass, basal metabolism, and total energy expenditure. It also aims to assess the relationship between adherence to the Mediterranean Diet and the onset of stroke and cognitive decline, as well as examine stroke severity (ischemic or hemorrhagic) and its association with Mediterranean Diet adherence (MEDAS questionnaire). Additionally, the study will explore the link between diet adherence and cognitive deficits, and measure changes in biological and anthropometric parameters as a result of adopting the Mediterranean Diet.\n\nPhase 2 is an interventional dietary study designed to evaluate the effects of the Mediterranean Diet, enriched with either extra virgin olive oil or walnuts, on stroke incidence and cognitive decline in patients with CAA and CADASIL.",[28,181],"CAA - Cerebral Amyloid Angiopathy",[183,58,184,185,186,187],"CADASIL","Mediterranean Diet","Nutritional status","Cognitive decline","Stroke incidence","2025-04-11",{"date":190,"type":33},"2025-04-18",{"date":192,"type":33},"2024-10-10",{"date":194,"type":22},"2026-07-31",{"name":98,"class":40},{"id":197,"slug":198,"hasResults":11,"nctId":199,"briefTitle":200,"officialTitle":201,"acronym":202,"eligibilityCriteria":203,"healthyVolunteers":11,"sex":17,"minAge":204,"maxAge":4,"enrollmentInfo":205,"targetDuration":207,"studyType":110,"phases":4,"briefSummary":208,"conditions":209,"keywords":212,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":217,"lastUpdatePostDateStruct":218,"startDateStruct":220,"completionDateStruct":222,"leadSponsor":224,"locationsCount":41},"100495682","prognosis-of-cerebral-small-vessel-disease-100495682","NCT05734378","Prognosis of Cerebral Small Vessel Disease","Prognosis of Cerebral Small Vessel Disease - a Prospective Cohort Study (PRO-SVD)","PRO-SVD","Inclusion Criteria:\n\n* Hypertensive deep perforator arteriolopathy (DPA), clinically symptomatic with either ICH, ischaemic stroke, cognitive impairment or severe radiological manifestation (Fazekas ≥II)\n* Cerebral amyloid angiopathy (CAA according to modified Boston or Edinburgh criteria), clinically symptomatic with either ICH (including cSAH), amyloid spells, cognitive impairment or severe radiological manifestation (CMB≥2)\n* Other SVD (i.e. CADASIL or other sporadic or genetic SVD)\n\nExclusion Criteria:\n\n* Life expectancy of \\\u003C6 months due to not-SVD related causes (i.e. cancer)\n* Patient is unlikely to attend follow-up visits","16 Years",{"count":206,"type":22},900,"1 Year","Prognosis of small vessel disease (SVD) depends on the underlying type of SVD and index manifestation.\n\nThe aim of this prospective, observational cohort study is to determine the risk of different outcome events among patients with SVD according to the type of index presentation.",[28,210,211,181],"Small Vessel Cerebrovascular Disease","Cadasil",[213,58,214,215,216,183],"small vessel disease","cerebral amyloid angiopathy","hypertensive arteriopathy","deep perforator arteriopathy","2023-03-06",{"date":219,"type":33},"2023-03-08",{"date":221,"type":33},"2020-12-01",{"date":223,"type":22},"2030-11-30",{"name":225,"class":40},"Insel Gruppe AG, University Hospital Bern"]